Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

This program supports preclinical and clinical research to develop interventions to prevent or treat substance use disorders and overdose, including medications, devices, digital therapeutics, and behavioral or integrative treatments. It is open to a wide range of applicants, including nonprofits, universities, for-profit organizations, governments, tribal organizations, faith-based or community-based organizations, and foreign organizations, and foreign components are allowed. Application budgets are limited to $3 million per year in direct costs, and the maximum project period is 5 years, with up to 2 years for UG3 and 3 years for UH3. No cost sharing is required. Applications involving foreign subawards or subcontracts are not allowed, and behavioral intervention studies are limited to NIH Stages I through III, while alcohol-only and effectiveness-only studies are not responsive.

✳ AI-generated summary — verify against the announcement

• Education
• Health
• Research & Discovery
• Technology & Product Development
• Patients & People with Health Conditions
• Biomedical & Disease Research
• Substance Use & Addiction

• ✓ City or township governments
• ✓ County governments
• ✓ For-profit organizations other than small businesses
• ✓ Independent school districts
• ✓ Native American tribal governments (Federally recognized)
• ✓ Native American tribal organizations (other than Federally recognized)
• ✓ Nonprofits with 501(c)(3) status (other than higher education)
• ✓ Nonprofits without 501(c)(3) status (other than higher education)
• ✓ Others
• ✓ Private institutions of higher education
• ✓ Public and State controlled institutions of higher education
• ✓ Public housing authorities / Indian housing authorities
• ✓ Small businesses
• ✓ Special district governments
• ✓ State governments